Monitoring Protocols

By Kyle Kingsley, MD | Medical Director, LiteWell

Starting a medication is a single event. Managing it safely is an ongoing process. In hormone health and metabolic medicine, the difference between a good outcome and a preventable complication is usually monitoring — the structured, scheduled reassessment that catches problems early and confirms that treatment is doing what it is supposed to do.

This article explains how LiteWell monitors patients, what we track, and why. The specifics below are illustrative of our standards; every patient’s monitoring plan is individualized to their therapy, history, and response.

Why monitoring is non-negotiable

Any therapy powerful enough to help is powerful enough to require oversight. Testosterone, menopausal hormone therapy, and metabolic agents such as GLP-1 receptor agonists all carry predictable effects that must be measured, not assumed. Guideline bodies — the Endocrine Society and AUA for testosterone, The Menopause Society and ACOG for hormone therapy, the ADA and AACE for metabolic care — build scheduled monitoring directly into their standards of care.

A clinic that prescribes without monitoring is not offering a shortcut. It is removing a safety system. We treat the ability and willingness to monitor as a condition of treatment; when it cannot be assured, therapy may not be appropriate — see When Treatment Is Not Appropriate].

The two phases of monitoring

Baseline (before therapy). Before starting, we establish a clear picture: the relevant labs if helpful, symptoms, and risk factors that let us confirm the indication and detect change later. You cannot interpret a follow-up value without a baseline to compare it to. Baseline testing is part of our [Clinical Evaluation Standards].

Ongoing (during therapy). Once treatment begins, monitoring follows a defined cadence — typically more frequently early, as we confirm response and safety, then spaced out once a patient is stable. At each checkpoint we ask three questions: *Is it working? Is it safe? Is the dose correct for this patient?*

What we monitor, and why

The categories below are examples of how monitoring maps to therapy. Exact tests, thresholds, and intervals are set by the treating clinician.

Testosterone therapy (men and women)

• **Symptom and function response** — the actual point of treatment.
• **Hormone levels** — to confirm we are dosing to a physiologic target, not chasing a number.
• **Hematocrit / red blood cell mass** — testosterone can raise it; unchecked erythrocytosis is a known risk.
• **Prostate-related surveillance in men** (e.g., PSA and clinical assessment) per age and risk.
• **Cardiovascular and metabolic factors** as clinically indicated.

Menopausal and female hormone therapy

• **Symptom control and quality of life** against the treatment goals.
• **Periodic risk reassessment** — the benefit-risk balance shifts over time and is revisited, not set once.
• **Breast and gynecologic health surveillance** consistent with age-appropriate screening.

Metabolic and weight-management therapy

• **Weight trajectory and body-composition trend**, not just the scale.
• **Metabolic markers** — glucose, lipids, and related labs as indicated.
• **Side-effect surveillance** — gastrointestinal tolerance, hydration, and other predictable effects.
• **Nutritional adequacy and lean-mass preservation**, so weight loss is healthy loss.

Cadence: front-loaded, then stable

Monitoring is not evenly spaced. Early in therapy, checkpoints are closer together — this is when dose adjustments happen and when early side effects surface. Once a patient reaches a stable, effective, well-tolerated regimen, intervals lengthen to a maintenance schedule, commonly anchored to periodic reviews at least annually with interim checks as needed. Any dose change, new symptom, or change in health status resets the clock.

When monitoring changes the plan

Monitoring only matters if we act on it. A rising hematocrit may prompt a dose reduction, a change in delivery, or a pause. A lack of symptomatic benefit despite adequate levels prompts us to reconsider the diagnosis rather than escalate blindly. A new risk factor may shift the risk-benefit balance enough to taper or stop — a decision covered in When Treatment Is Not Appropriate]. The protocol exists to inform action, not to generate paperwork.

The patient’s role

Monitoring is a partnership. Showing up for scheduled labs and visits, reporting new symptoms promptly, and being honest about adherence and side effects are what make safe, effective long-term therapy possible. We make the schedule clear at the outset so there are no surprises.

Key takeaways

• Monitoring is built into therapy from the start, not added when something goes wrong.
• We track whether treatment is working, whether it is safe, and whether the dose is right — at every checkpoint.
• Monitoring is front-loaded early in therapy and spaced out once a patient is stable.
• Results drive action: dose changes, pauses, or reassessment of the diagnosis.

Frequently asked questions

How often will I need labs?

More often at the start while we confirm response and safety, then less often once you are stable — commonly at least annually with interim checks as needed. Your clinician sets the exact schedule.

What happens if a value comes back abnormal?

We interpret it in context and act — which may mean adjusting the dose, changing the approach, or pausing therapy. An abnormal result is information, and we respond to it.

Can I stay on therapy without regular monitoring?

No. Ongoing monitoring is a safety requirement for the therapies we manage, not an optional add-on.

Sources and further reading

Our monitoring standards draw on clinical practice guidance from the Endocrine Society, the American Urological Association (AUA), The Menopause Society, ACOG, the American Diabetes Association (ADA), and the American Association of Clinical Endocrinology (AACE), alongside FDA labeling for the therapies we manage. [Reviewing physician to attach specific guideline citations and links.]

This article is for general educational purposes and does not constitute medical advice or establish a physician-patient relationship. Individual monitoring plans require a personal evaluation by a licensed clinician.

Related reading: [Clinical Evaluation Standards] · [When Treatment Is Not Appropriate] · [Medication Safety Practices]